Goal 3
ANNUAL
REPORT 2023
Goal 3
ANNUAL
REPORT 2023
Goal 3
ANNUAL
REPORT 2023
Goal 3: Strengthen ANZUP’s capacity for practice-changing clinical trials
ANZUP continues to review, modify and improve its systems, procedures and governance principles to maintain the delivery of our strategic plan. Our organizational structure is designed to align with corporate governance and operational responsibilities. The Board, consisting of the Directors of the Company, assumes accountability for corporate governance, financial management, reporting and compliance, and regular policy review. This ensures the establishment of a robust quality management system to support the execution of our strategic objectives.
ANZUP’s Idea Generation Workshops have been simplified with the use of templates. We actively seek input from our subcommittees and broader membership to identify opportunities for new or revised tools that enhance collaboration and expand our capabilities.
As the number of ANZUP studies continues to increase and the membership steadily grows, we recognise the importance of clearly defined decision-making processes and allocation of duties. The quality and integrity of ANZUP operations are supported by documented processes and policies.
The delivery of our strategic plan relies on ongoing fundraising efforts. Our fundraising plan aims to broaden cost-effective, sustainable, and regular revenue streams through various fundraising activities.
The Below the Belt Research Fund plays a crucial role in supporting ANZUP trials, utilising the funds raised through events such as the Sydney and Melbourne Pedalthons, the Below the Belt #YourWay Challenge, and Below the Belt events. To date, the Below the Belt Research Fund has raised over $2.05 million, contributing significantly to our research endeavours.
The ASM also supports the financial sustainability of ANZUP. ANZUP continues to expand the ASM by creating and presenting a high-quality scientific program. In 2022 our ASM returned back to face-to-face after 3 years due to the COVID-19.